217480 — SD Biotechnologies Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeMicro Cap

Annual income statement for SD Biotechnologies Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	156,259	140,725	124,681	56,574	46,943
Cost of Revenue
Gross Profit	50,714	51,560	36,201	18,360	19,797
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	173,885	147,564	165,983	89,678	59,021
Operating Profit	-17,626	-6,839	-41,302	-33,105	-12,078
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-17,048	-9,235	-42,109	-37,872	-10,033
Provision for Income Taxes
Net Income After Taxes	-19,628	-9,765	-45,149	-37,890	-10,033
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-18,445	-8,668	-43,567	-72,749	-4,608
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-18,445	-8,668	-43,567	-72,749	-4,608
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-993	-376	-2,352	-2,292	-299
Dividends per Share